Dr. Allen Davidoff reports

XORTX ANNOUNCES CHANGE OF AUDITOR

XORTX Therapeutics Inc. has changed its auditor from Smythe LLP, chartered professional accountants, to Davidson & Company LLP, chartered professional accountants, effective Jan. 16, 2025.

XORTX's board of directors accepted the resignation of the former auditor, as of Jan. 16, 2025, and appointed the successor auditor as the new auditor of the company effective Jan. 16, 2025, and to hold office until the close of the company's next annual general meeting of shareholders.

There were no reservations in the former auditor's audit reports for any financial period during which the former auditor was the company's auditor. There are no "reportable events" (as the term is defined in National Instrument 51-102 -- Continuous Disclosure Obligations) between the company and the former auditor.

In accordance with National Instrument 51-102, the notice of change of auditor, together with the required letters from the former auditor and the successor auditor, have been reviewed by the company's audit committee and board of directors and have been filed on the company's SEDAR+ profile.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: (1) the company's lead program, XRx-008, for ADPKD (autosomal dominant polycystic kidney disease); (2) the company's XRx-026 program for the treatment of allopurinol-intolerant gout; and (3) the company's secondary program in XRx-101 for acute kidney and other acute organ injury associated with coronavirus/COVID-19 infection. In addition, XRx-225 is a preclinical-stage program for Type 2 diabetic nephropathy. XORTX is working to advance its clinical-development-stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, the company is dedicated to developing medications to improve the quality of life and health of kidney disease patients and individuals with gout.